金斯瑞生物科技股份有限公司在2025年上半年展示了盈利规模和战略领导力，通过加速增长和创新确立了明确的行业领先地位-动脉网

GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation

CISION 等信源发布 2025-08-17 20:01



可切换为仅中文







Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation

全球影响力提升、一流的创新能力和ESG卓越表现，为持续创造价值奠定基础。

PISCATAWAY, N.J.

新泽西州皮斯卡塔韦

，

Aug. 17, 2025

2025年8月17日

/PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global pioneer in life sciences innovation, today announced outstanding interim results for the first half of 2025, underscoring its ability to deliver profitable growth at scale through strategic globalization, differentiated technology, and relentless innovation..

/PRNewswire/ -- 金斯瑞生物科技股份有限公司（HK.1548），全球生命科学创新的先驱，今日宣布了2025年上半年的卓越中期业绩，凸显了其通过战略性全球化、差异化技术和不懈创新实现规模化盈利增长的能力。

Fueled by robust demand across all business segments and expansion into key international markets, GenScript achieved consolidated revenue of approximately

受到所有业务部门的强劲需求和向关键国际市场的扩张推动，金斯瑞实现了约

US$518.8 million

5亿1880万美元

for H1 2025, reflecting an exceptional 81.9% year-over-year increase. Gross profit rose 140.1% to

对于2025年上半年，反映出同比异常增长81.9%。毛利润增长了140.1%，达到

US$320.6 million

3.206亿美元

, while adjusted net profit from continuing operations surged 509.6% to

，经调整的持续经营业务净利激增509.6%，达到

US$178 million

1.78亿美元

, demonstrating not only rapid growth but superior operational leverage and margin resilience.

，不仅展示了快速增长，还展现了卓越的运营杠杆和利润韧性。

H1 2025 Highlights and Financial Performance

2025年上半年亮点与财务表现

Revenue:

收入：

US$518.8 million

5.188亿美元

(+81.9%); reflecting broad-based growth across all business segments and geographies.

（+81.9%）；反映了所有业务部门和地区的广泛增长。

Gross Profit:

毛利润：

US$320.6 million

3.206亿美元

(+140.1%); driven by enhanced capacity utilization and premium product mix.

（+140.1%）；得益于产能利用率的提升和高端产品组合。

Adjusted Net Profit from Continuing Operations:

调整后持续经营净利润：

US$178.0 million

1.78亿美元

(+509.6%); underscoring highly scalable profitability and improved operational leverage.

（+509.6%）；突显了高度可扩展的盈利能力和运营杠杆的提升。

Global Presence:

全球存在：

Meaningful growth across all regions, driven by elevated contribution from international markets

所有地区均有显著增长，这主要得益于国际市场贡献的提升。

Sustainability Leadership:

可持续发展领导力：

Industry-leading ESG ratings reinforcing long-term stakeholder value

行业领先的ESG评级，强化长期利益相关者价值

'Our first-half results powerfully affirm the strength of GenScript's innovation-led, commercially driven global strategy,' said

“我们上半年的业绩有力地证明了金斯瑞以创新为引领、以商业为导向的全球战略的正确性，”

Sherry Shao

邵雪莉

, Rotating CEO of GenScript Biotech. 'We remain committed to deepening R&D investment, expanding production capacity worldwide, and accelerating market penetration to deliver sustainable growth and superior value to our customers and shareholders.'

金斯瑞生物科技股份有限公司轮值首席执行官表示：“我们仍将致力于加大研发投入、扩大全球产能并加速市场渗透，从而为我们的客户和股东带来可持续的增长与卓越的价值。”

Strategic Growth Drivers and Segment Highlights:

战略增长动力与细分亮点：

Innovation and Gene-to-Protein Platform Excellence

创新与基因到蛋白质平台的卓越性

The Life Science Services and Products segment generated

生命科学服务与产品部门产生

US$247.6 million

2.476亿美元

in revenue (+11.3% YoY), powered by breakthrough increases in gene synthesis throughput. The protein business demonstrated a remarkable 52% uplift, capitalizing on surging demand, especially from AI-driven drug discovery innovators. This segment's growth is bolstered by expanding reagent and consumable offerings and investments in automated 'lights-out' manufacturing, enabling both scale and profitability..

收入增长了 11.3%（同比增长），这得益于基因合成通量的突破性提升。蛋白质业务表现尤为突出，实现了 52% 的显著增长，充分利用了不断增长的需求，特别是来自人工智能驱动的药物发现创新者的需求。该领域的增长得益于试剂和耗材产品的扩展以及对自动化“熄灯”制造的投资，从而实现了规模效应和盈利能力。

CDMO Business Rebounds with a return to revenue growth after the industry headwind

CDMO业务在行业逆风后反弹，恢复收入增长。

GenScript's biologics development CDMO services, operated under ProBio, reported

金斯瑞的生物制品开发CDMO服务，由ProBio运营，据报道

US$246.9 M

2.469亿美元

in revenue, an extraordinary 511.1% increase year-over-year. Adjusted gross margin expanded dramatically to 73.6%, reflecting improved capacity utilization and operational efficiencies. Excluding a one-time upfront payment tied to collaboration with LaNova, the segment sustained strong double-digit growth.

收入同比增长了惊人的511.1%。调整后的毛利率大幅扩大至73.6%，反映出产能利用率的提高和运营效率的提升。如果不考虑与LaNova合作相关的一次性预付款，该业务板块继续保持强劲的两位数增长。

ProBio has out-licensed 16 assets—4 in clinical development—and impending milestones such as the potential CD3 VHH out-licensing by late 2025 or early 2026, offer robust visibility into future revenue streams and underline long-term growth potential..

ProBio 已对外授权了 16 项资产，其中 4 项处于临床开发阶段。预计到 2025 年底或 2026 年初，潜在的 CD3 VHH 对外授权等即将到来的里程碑，将为未来的收入来源提供强有力的可见性，并凸显长期增长潜力。

Industrial synthetic biology products' Market Leadership and Product Innovation

工业合成生物学产品的市场领导力与产品创新

Bestzyme, Industrial synthetic biology products unit, grew its revenue by 8.4%, driven by market share gains for its innovative enzyme portfolio and continued trust from key accounts.

最佳酶，工业合成生物学产品部门，由于其创新酶组合的市场份额增加和主要客户的持续信任，收入增长了8.4%。

With 61 patents granted and 61 new applications filed, Bestzyme is leading industry innovation. Its innovative synthetic biologic product, sweet protein, has earned FDA GRAS status, and the commercial manufacturing facility is expected to commence operations in mid-2026 .

拥有61项已授权专利和61项新申请，Bestzyme正引领行业创新。其创新的合成生物产品——甜蛋白，已获得FDA的GRAS认证，商业化生产设施预计将于2026年年中投入运营。

Strengthening Global Reach and Market Position for the Life Science Services and Products

加强生命科学服务和产品的全球影响力和市场地位

GenScript's global production and R&D footprint—with major facilities in the U.S.,

金斯瑞在全球的生产和研发足迹——在美国拥有主要设施，

Europe

欧洲

, and Asia—supports over 60% automation penetration, enabling resilient supply chains and rapid responsiveness to customers' evolving needs. The company's

，以及亚洲——支持超过60%的自动化渗透率，能够实现供应链的弹性并快速响应客户不断变化的需求。公司

August 8

8月8日

global brand relaunch, paired with its industry-leading Net Promoter Score, strengthens customer loyalty and commercial momentum, driving win rates, pricing power, and adoption of integrated, higher-margin solutions.

全球品牌重塑，加上其行业领先的净推荐值，加强了客户忠诚度和商业势头，提高了胜率、定价能力和集成高利润解决方案的采用率。

Unwavering Commitment to ESG, Driving Sustainable Competitive Advantage

对ESG的坚定承诺，推动可持续竞争优势

The Group continues to lead in sustainability, with its ESG framework aligned to global best practices. The group has earned top-tier recognition, including an MSCI AA rating, EcoVadis Silver Medal, Sustainalytics 'Low Risk' designation, an improved S&P Global Corporate Sustainability Assessment score of 60, and inclusion in the FTSE4Good Index Series.

该集团在可持续发展方面继续保持领先地位，其ESG框架与全球最佳实践保持一致。该集团获得了多项顶级认可，包括MSCI AA评级、EcoVadis银牌、Sustainalytics“低风险”称号、S&P Global企业可持续发展评估得分提升至60分，以及被纳入FTSE4Good指数系列。

Its science-based carbon reduction targets are validated by the SBTi, supported by commitments through membership in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative..

其基于科学的碳减排目标已通过SBTi验证，并通过加入联合国全球契约和医药供应链倡议获得承诺支持。

These actions underscore GenScript's commitment to responsible growth and enhance its appeal to investors who prioritize ESG as a key driver of sustainable, long-term value.

这些行动强调了金斯瑞对负责任增长的承诺，并增强了其对那些将 ESG 视为可持续、长期价值的关键驱动因素的投资者的吸引力。

Outlook

展望

GenScript anticipates continued growth backed by scaling automation, global brand strength, and an expanding pipeline of innovative solutions. The company is well positioned to sustain its biotech leadership, delivering differentiated solutions and creating elevated shareholder value in an evolving global healthcare and biotech landscape..

金斯瑞预计，在自动化规模扩大、全球品牌实力增强以及创新解决方案渠道不断扩大的推动下，公司将继续保持增长。公司在不断发展的全球医疗保健和生物技术领域中，具备维持其生物技术领导地位的优势，提供差异化解决方案，并创造更高的股东价值。

About GenScript Biotech Corporation

关于金斯瑞生物科技股份有限公司

Founded in 2002 in

成立于2002年

New Jersey

新泽西州

, GenScript Biotech Corporation accelerates innovation in healthcare and consumer goods by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,700 employees and has served more than 200,000 customers across 100 countries..

，金斯瑞生物科技股份有限公司通过为研究人员和公司提供开发突破性治疗和产品所需的构建模块，加速了医疗保健和消费品领域的创新。在“通过生物技术让人与自然更健康”的使命指引下，并作为值得信赖的全球领导者，金斯瑞拥有超过5700名员工，已为遍布100个国家的20多万客户提供服务。

Learn more here:

了解更多请点击这里：

https://www.genscript.com

SOURCE GenScript Biotech Corporation

来源：金斯瑞生物科技股份有限公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+